T1	intervention 25 40	zoledronic acid
T2	condition 44 53	bone loss
T3	eligibility 373 492	Postmenopausal patients with stage I-III hormone receptor-positive breast cancer who received tamoxifen for 2.5-3 years
T4	intervention 520 529	letrozole
T5	intervention-participants 553 555	47
T6	control 560 567	without
T7	control-participants 573 575	43
T8	duration 612 619	2 years
T9	outcome-Measure 646 722	percent change from baseline in lumbar spine (LS) bone mineral density (BMD)
T10	No-of-participants 740 746	Ninety
T11	No-of-participants 757 759	86
T12	average-age 792 812	59 years (42.9-83.6)
T13	outcome 980 990	LS T-score
T14	outcome 1065 1095	Change over time in LS T-score
T15	outcome 1187 1246	No fractures, renal dysfunction or osteonecrosis of the jaw
T16	outcome 1266 1282	toxicity profile
